{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:38:28Z","timestamp":1787841508868,"version":"build-2784847793"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12282-026-01900-0","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T08:44:18Z","timestamp":1786092258000},"page":"978-990","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-generation endocrine therapy in HR+\/HER2\u2009\u2212\u2009breast cancer: oral SERDs, ER-targeting innovations, and ctDNA-driven ESR1 mutation\u2013guided switching"],"prefix":"10.1007","volume":"33","author":[{"given":"Nan","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoshuai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuzhou","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"6","key":"1900_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/CCO.0000000000001085","volume":"36","author":"L Ascione","year":"2024","unstructured":"Ascione L, Castellano G, Curigliano G, Zagami P. Endocrine therapy for early breast cancer in the era of oral selective estrogen receptor degraders: challenges and future perspectives. Curr Opin Oncol. 2024;36(6):465\u201373. https:\/\/doi.org\/10.1097\/CCO.0000000000001085 . Epub 2024 Aug 12. PMID: 39246179; PMCID: PMC11460762.","journal-title":"Curr Opin Oncol"},{"key":"1900_CR2","doi-asserted-by":"publisher","unstructured":"Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Di\u00e9ras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016;375(20):1925\u20131936. https:\/\/doi.org\/10.1056\/NEJMoa1607303. PMID: 27959613.","DOI":"10.1056\/NEJMoa1607303"},{"issue":"1","key":"1900_CR3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-018-0620-6","volume":"11","author":"A Souza","year":"2018","unstructured":"D\u2019, Souza A, Spicer D, Lu J. Overcoming endocrine resistance in metastatic hormone receptor-positive breast cancer. J Hematol Oncol. 2018;11(1):80. https:\/\/doi.org\/10.1186\/s13045-018-0620-6 . PMID: 29891002; PMCID: PMC5996460.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1900_CR4","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/ng.2822","volume":"45","author":"W Toy","year":"2013","unstructured":"Toy W, Shen Y, Won H, Green B, Sakr RA, Will M, Li Z, Gala K, Fanning S, King TA, Hudis C, Chen D, Taran T, Hortobagyi G, Greene G, Berger M, Baselga J, Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439\u201345. https:\/\/doi.org\/10.1038\/ng.2822 . Epub 2013 Nov 3. PMID: 24185512; PMCID: PMC3903423.","journal-title":"Nat Genet"},{"issue":"10","key":"1900_CR5","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/nrclinonc.2015.117","volume":"12","author":"R Jeselsohn","year":"2015","unstructured":"Jeselsohn R, Buchwalter G, De Angelis C, Brown M, Schiff R. ESR1 mutations\u2014a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol. 2015;12(10):573\u201383. https:\/\/doi.org\/10.1038\/nrclinonc.2015.117 . Epub 2015 Jun 30. PMID: 26122181; PMCID: PMC4911210.","journal-title":"Nat Rev Clin Oncol"},{"key":"1900_CR6","doi-asserted-by":"publisher","unstructured":"Chandarlapaty S, Chen D, He W, Sung P, Samoila A, You D, Bhatt T, Patel P, Voi M, Gnant M, Hortobagyi G, Baselga J, Moynahan ME. Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. JAMA Oncol. 2016;2(10):1310\u20131315. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1279. Erratum in: JAMA Oncol. 2019;5(1):122. doi: 10.1001\/jamaoncol.2018.5678.","DOI":"10.1001\/jamaoncol.2016.1279"},{"issue":"313","key":"1900_CR7","doi-asserted-by":"publisher","first-page":"313ra182","DOI":"10.1126\/scitranslmed.aac7551","volume":"7","author":"G Schiavon","year":"2015","unstructured":"Schiavon G, Hrebien S, Garcia-Murillas I, Cutts RJ, Pearson A, Tarazona N, Fenwick K, Kozarewa I, Lopez-Knowles E, Ribas R, Nerurkar A, Osin P, Chandarlapaty S, Martin LA, Dowsett M, Smith IE, Turner NC. Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer. Sci Transl Med. 2015;7(313):313ra182. https:\/\/doi.org\/10.1126\/scitranslmed.aac7551 . PMID: 26560360; PMCID: PMC4998737.","journal-title":"Sci Transl Med"},{"issue":"1","key":"1900_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1093\/annonc\/mdx483","volume":"29","author":"C Fribbens","year":"2018","unstructured":"Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O\u2019Leary B, Kilburn L, Howarth K, Epstein M, Green E, Rosenfeld N, Ring A, Johnston S, Turner N. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol. 2018;29(1):145\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdx483 . PMID: 29045530; PMCID: PMC6264798.","journal-title":"Ann Oncol"},{"issue":"11","key":"1900_CR9","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S1470-2045(22)00555-1","volume":"23","author":"FC Bidard","year":"2022","unstructured":"Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D\u2019Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, Andr\u00e9 F, Arnould L, Pradines A, Bi\u00e8che I, Callens C, Lemonnier J, Berger F, Delaloge S. PADA-1 investigators. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2022;23(11):1367\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(22)00555-1 . Epub 2022 Sep 29. PMID: 36183733.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1900_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","volume":"393","author":"FC Bidard","year":"2025","unstructured":"Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, Kalinsky K, Iwata H, Chia S, Fasching PA, Brufsky A, Nowecki Z, Pascual J, Moreau L, Chen SC, Karadurmus N, Gal-Yam EN, Jung KH, Pernas S, McClain S, He W, Klinowska T, Huang-Bartlett C, Turner NC. SERENA-6 Study Group. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025;393(6):569\u201380. https:\/\/doi.org\/10.1056\/NEJMoa2502929 . Epub 2025 Jun 1. PMID: 40454637.","journal-title":"N Engl J Med"},{"key":"1900_CR11","doi-asserted-by":"publisher","unstructured":"Klinge CM. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001;29(14):2905\u201319. https:\/\/doi.org\/10.1093\/nar\/29.14.2905 . PMID: 11452016; PMCID: PMC55815.","DOI":"10.1093\/nar\/29.14.2905"},{"key":"1900_CR12","doi-asserted-by":"publisher","unstructured":"Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233\u201347. https:\/\/doi.org\/10.1146\/annurev-med-070909-182917 . PMID: 20887199; PMCID: PMC3656649.","DOI":"10.1146\/annurev-med-070909-182917"},{"issue":"12","key":"1900_CR13","doi-asserted-by":"publisher","first-page":"5557","DOI":"10.1210\/en.2006-0729","volume":"147","author":"K Moriarty","year":"2006","unstructured":"Moriarty K, Kim KH, Bender JR. Minireview: estrogen receptor-mediated rapid signaling. Endocrinology. 2006;147(12):5557\u201363. https:\/\/doi.org\/10.1210\/en.2006-0729 . Epub 2006 Aug 31. PMID: 16946015.","journal-title":"Endocrinology"},{"key":"1900_CR14","doi-asserted-by":"crossref","unstructured":"Osborne CK, Shou J, Massarweh S, Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer. Clin Cancer Res. 2005;11(2 Pt 2):865s-70s. PMID: 15701879.","DOI":"10.1158\/1078-0432.865s.11.2"},{"issue":"4","key":"1900_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1159\/000354757","volume":"8","author":"SP Hasson","year":"2013","unstructured":"Hasson SP, Rubinek T, Ryvo L, Wolf I. Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase\/akt\/mammalian target of rapamycin signaling pathway. Breast Care (Basel). 2013;8(4):248\u201355. PMID: 24415977; PMCID: PMC3808218.","journal-title":"Breast Care (Basel)"},{"issue":"113","key":"1900_CR16","first-page":"65","volume":"21","author":"L Spring","year":"2016","unstructured":"Spring L, Bardia A, Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4\/6-retinoblastoma pathway with selective CDK 4\/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med. 2016;21(113):65\u201374. PMID: 26896604; PMCID: PMC5477652.","journal-title":"Discov Med"},{"key":"1900_CR17","doi-asserted-by":"publisher","first-page":"666","DOI":"10.3389\/fonc.2019.00666","volume":"9","author":"A McCartney","year":"2019","unstructured":"McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F, Galardi F, Risi E, De Santo I, Benelli M, Malorni L, Di Leo A. Mechanisms of Resistance to CDK4\/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice. Front Oncol. 2019;9:666. https:\/\/doi.org\/10.3389\/fonc.2019.00666 . PMID: 31396487; PMCID: PMC6664013.","journal-title":"Front Oncol"},{"issue":"12","key":"1900_CR18","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1038\/ng.2823","volume":"45","author":"DR Robinson","year":"2013","unstructured":"Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, Kalyana-Sundaram S, Wang R, Ning Y, Hodges L, Gursky A, Siddiqui J, Tomlins SA, Roychowdhury S, Pienta KJ, Kim SY, Roberts JS, Rae JM, Van Poznak CH, Hayes DF, Chugh R, Kunju LP, Talpaz M, Schott AF, Chinnaiyan AM. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45(12):1446\u201351. https:\/\/doi.org\/10.1038\/ng.2823 . Epub 2013 Nov 3. PMID: 24185510; PMCID: PMC4009946.","journal-title":"Nat Genet"},{"key":"1900_CR19","doi-asserted-by":"publisher","first-page":"e12792","DOI":"10.7554\/eLife.12792","volume":"5","author":"SW Fanning","year":"2016","unstructured":"Fanning SW, Mayne CG, Dharmarajan V, Carlson KE, Martin TA, Novick SJ, Toy W, Green B, Panchamukhi S, Katzenellenbogen BS, Tajkhorshid E, Griffin PR, Shen Y, Chandarlapaty S, Katzenellenbogen JA, Greene GL. Estrogen receptor alpha somatic mutations Y537S and D538G confer breast cancer endocrine resistance by stabilizing the activating function-2 binding conformation. Elife. 2016;5:e12792. https:\/\/doi.org\/10.7554\/eLife.12792 . PMID: 26836308; PMCID: PMC4821807.","journal-title":"Elife"},{"key":"1900_CR20","doi-asserted-by":"publisher","first-page":"175883592211136","DOI":"10.1177\/17588359221113694","volume":"14","author":"MR Lloyd","year":"2022","unstructured":"Lloyd MR, Wander SA, Hamilton E, Razavi P, Bardia A. Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. Ther Adv Med Oncol. 2022;14:17588359221113694. PMID: 35923930; PMCID: PMC9340905.","journal-title":"Ther Adv Med Oncol"},{"issue":"18","key":"1900_CR21","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1200\/JCO.23.00638","volume":"41","author":"HJ Burstein","year":"2023","unstructured":"Burstein HJ, DeMichele A, Somerfield MR, Henry NL. Biomarker Testing and Endocrine and Targeted Therapy in Metastatic Breast Cancer Expert Panels. Testing for ESR1 Mutations to Guide Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Rapid Recommendation Update. J Clin Oncol. 2023;41(18):3423\u20135. https:\/\/doi.org\/10.1200\/JCO.23.00638 . Epub 2023 May 17. PMID: 37196213.","journal-title":"J Clin Oncol"},{"issue":"12","key":"1900_CR22","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, Cort\u00e9s J, de Azambuja E, DeMichele A, Dent R, Fenlon D, Gligorov J, Hurvitz SA, Im SA, Krug D, Kunz WG, Loi S, Penault-Llorca F, Ricke J, Robson M, Rugo HS, Saura C, Schmid P, Singer CF, Spanic T, Tolaney SM, Turner NC, Curigliano G, Loibl S, Paluch-Shimon S, Harbeck N. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395. https:\/\/doi.org\/10.1016\/j.annonc.2021.09.019 . Epub 2021 Oct 19. PMID: 34678411.","journal-title":"Ann Oncol"},{"issue":"8","key":"1900_CR23","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, Italiano A, Lindberg J, Merker JD, Montagut C, Normanno N, Pantel K, Pentheroudakis G, Popat S, Reis-Filho JS, Tie J, Seoane J, Tarazona N, Yoshino T, Turner NC. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33(8):750\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2022.05.520 . Epub 2022 Jul 6. PMID: 35809752.","journal-title":"Ann Oncol"},{"key":"1900_CR24","doi-asserted-by":"publisher","first-page":"102642","DOI":"10.1016\/j.ctrv.2023.102642","volume":"121","author":"K Venetis","year":"2023","unstructured":"Venetis K, Pepe F, Pescia C, Cursano G, Criscitiello C, Frascarelli C, Mane E, Russo G, Taurelli Salimbeni B, Troncone G, Guerini Rocco E, Curigliano G, Fusco N, Malapelle U. ESR1 mutations in HR+\/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing. Cancer Treat Rev. 2023;121:102642. https:\/\/doi.org\/10.1016\/j.ctrv.2023.102642 . Epub 2023 Oct 13. PMID: 37864956.","journal-title":"Cancer Treat Rev"},{"key":"1900_CR25","doi-asserted-by":"crossref","unstructured":"Yarunin A, Ahlgren H, Chaki M, Morrow C, Li X, Longshore J. ESR1 ctDNA testing: literature review and comparison of assays for ESR1 mutation detection in advanced hormone receptor-positive breast cancer. Expert Rev Mol Diagn. 2025;25(12):903\u2013914. doi: 10.1080\/14737159.2025.2576021. Epub 2025 Nov 6. PMID: 41186491.","DOI":"10.1080\/14737159.2025.2576021"},{"issue":"3","key":"1900_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1093\/annonc\/mdy552","volume":"30","author":"C Abbosh","year":"2019","unstructured":"Abbosh C, Swanton C, Birkbak NJ. Clonal haematopoiesis: a source of biological noise in cell-free DNA analyses. Ann Oncol. 2019;30(3):358\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdy552 . PMID: 30649226; PMCID: PMC6442654.","journal-title":"Ann Oncol"},{"issue":"9","key":"1900_CR27","doi-asserted-by":"publisher","first-page":"e2431722","DOI":"10.1001\/jamanetworkopen.2024.31722","volume":"7","author":"K Dickinson","year":"2024","unstructured":"Dickinson K, Sharma A, Agnihotram RV, Altuntur S, Park M, Meterissian S, Burnier JV. Circulating Tumor DNA and Survival in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. JAMA Netw Open. 2024;7(9):e2431722. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.31722 . PMID: 39235812; PMCID: PMC11378006.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"1900_CR28","doi-asserted-by":"publisher","first-page":"102235","DOI":"10.1016\/j.esmoop.2024.102235","volume":"9","author":"GA Martens","year":"2024","unstructured":"Martens GA, Demol J, Dedeurwaerdere F, Breyne J, De Smet K, De Jaeger P, De Smet D. Rational thresholding of circulating tumor DNA concentration for improved surveillance of metastatic breast cancer. ESMO Open. 2024;9(2):102235. https:\/\/doi.org\/10.1016\/j.esmoop.2024.102235 . Epub 2024 Feb 5. PMID: 38320429; PMCID: PMC10937210.","journal-title":"ESMO Open"},{"key":"1900_CR29","doi-asserted-by":"publisher","unstructured":"Lewis-Wambi JS, Jordan VC. Treatment of Postmenopausal Breast Cancer with Selective Estrogen Receptor Modulators (SERMs). Breast Dis. 2005\u20132006;24:93\u2013105. https:\/\/doi.org\/10.3233\/bd-2006-24108. PMID: 16917142.","DOI":"10.3233\/bd-2006-24108"},{"issue":"1","key":"1900_CR30","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1038\/sj.bjc.6601630","volume":"90","author":"JF Robertson","year":"2004","unstructured":"Robertson JF, Harrison M. Fulvestrant: pharmacokinetics and pharmacology. Br J Cancer. 2004;90(1):S7\u201310. https:\/\/doi.org\/10.1038\/sj.bjc.6601630 . PMID: 15094758; PMCID: PMC2750771.","journal-title":"Br J Cancer"},{"key":"1900_CR31","doi-asserted-by":"crossref","unstructured":"Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Results of the CONFIRM phase III trial comparing fulvestrant 250\u00a0mg with fulvestrant 500\u00a0mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010;28(30):4594\u2009\u2013\u2009600. doi: 10.1200\/JCO.2010.28.8415. Epub 2010 Sep 20. Erratum in: J Clin Oncol. 2011;29(16):2293. PMID: 20855825.","DOI":"10.1200\/JCO.2010.28.8415"},{"key":"1900_CR32","doi-asserted-by":"publisher","unstructured":"Bidard FC, Kaklamani VG, Neven P, Streich G, Montero AJ, Forget F, Mouret-Reynier MA, Sohn JH, Taylor D, Harnden KK, Khong H, Kocsis J, Dalenc F, Dillon PM, Babu S, Waters S, Deleu I, Garc\u00eda S\u00e1enz JA, Bria E, Cazzaniga M, Lu J, Aftimos P, Cort\u00e9s J, Liu S, Tonini G, Laurent D, Habboubi N, Conlan MG, Bardia A. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. J Clin Oncol. 2022;40(28):3246\u20133256. doi: 10.1200\/JCO.22.00338. Epub 2022 May 18. Erratum in: J Clin Oncol. 2023;41(23):3962. https:\/\/doi.org\/10.1200\/JCO.23.01239. PMID: 35584336; PMCID: PMC9553388.","DOI":"10.1200\/JCO.23.01239"},{"key":"1900_CR33","doi-asserted-by":"publisher","unstructured":"Oliveira M, Pominchuk D, Nowecki Z, Hamilton E, Kulyaba Y, Andabekov T, Hotko Y, Melkadze T, Nemsadze G, Neven P, Vladimirov V, Zamagni C, Denys H, Forget F, Horvath Z, Nesterova A, Ajimi M, Kirova B, Klinowska T, Lindemann JPO, Lissa D, Mathewson A, Morrow CJ, Traugottova Z, van Zyl R, Arkania E. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol. 2024;25(11):1424\u20131439. doi: 10.1016\/S1470-2045(24)00387-5. Erratum in: Lancet Oncol. 2025;26(3):e127. https:\/\/doi.org\/10.1016\/S1470-2045(25)00036-1. PMID: 39481395.","DOI":"10.1016\/S1470-2045(25)00036-1"},{"key":"1900_CR34","doi-asserted-by":"publisher","unstructured":"Hurvitz SA, Bardia A, Quiroga V, Park YH, Blancas I, Alonso-Romero JL, Vasiliev A, Adamchuk H, Salgado M, Yardley DA, Berzoy O, Zamora-Au\u00f1\u00f3n P, Chan D, Spera G, Xue C, Ferreira E, Badovinac Crnjevic T, P\u00e9rez-Moreno PD, L\u00f3pez-Valverde V, Steinseifer J, Fernando TM, Moore HM, Fasching PA. coopERA Breast Cancer study group. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study. Lancet Oncol. 2023;24(9):1029\u20131041. doi: 10.1016\/S1470-2045(23)00268-1. Erratum in: Lancet Oncol. 2023;24(11):e425. https:\/\/doi.org\/10.1016\/S1470-2045(23)00482-5. PMID: 37657462.","DOI":"10.1016\/S1470-2045(23)00482-5"},{"key":"1900_CR35","doi-asserted-by":"crossref","unstructured":"Bardia A, Schmid P, Mart\u00edn M, Hurvitz S, Jung K, Rimawi M, Saji S, Werutsky G, Harbeck N, Loi S, Ogiya A, Ruiz-Borrego M, Alacac\u0131o\u011flu A, Wu J, Ye C, Liste-Hermoso M, Withana N, Badovinac Crnjevic T, Shah M, P\u00e9rez-Moreno P, Geyer CE Jr. Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive, HER2-negative early breast cancer: Results from the global Phase III lidERA Breast Cancer trial. Presented at: San Antonio Breast Cancer Symposium (SABCS). 2025; 2025; San Antonio, TX, USA. Abstract GS1-10.","DOI":"10.1158\/1557-3265.SABCS25-GS1-10"},{"key":"1900_CR36","doi-asserted-by":"publisher","unstructured":"Jhaveri KL, Lim E, Jeselsohn R, Ma CX, Hamilton EP, Osborne C, Bhave M, Kaufman PA, Beck JT, Manso Sanchez L, Parajuli R, Wang HC, Tao JJ, Im SA, Harnden K, Yonemori K, Dhakal A, Neven P, Aftimos P, Pierga JY, Lu YS, Larson T, Jerez Y, Sideras K, Sohn J, Kim SB, Saura C, Bardia A, Sammons SL, Bacchion F, Li Y, Yuen E, Estrem ST, Rodrik-Outmezguine V, Nguyen B, Ismail-Khan R, Smyth L, Beeram M. Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia\/Ib EMBER Study. J Clin Oncol. 2024;42(35):4173\u20134186. doi: 10.1200\/JCO.23.02733. Epub 2024 Sep 6. Erratum in: J Clin Oncol. 2025;43(1):114. https:\/\/doi.org\/10.1200\/JCO-24-02470. PMID: 39241211; PMCID: PMC11637582.","DOI":"10.1200\/JCO-24-02470"},{"issue":"16","key":"1900_CR37","doi-asserted-by":"publisher","first-page":"3549","DOI":"10.1158\/1078-0432.CCR-23-3465","volume":"30","author":"SM Gough","year":"2024","unstructured":"Gough SM, Flanagan JJ, Teh J, Andreoli M, Rousseau E, Pannone M, Bookbinder M, Willard R, Davenport K, Bortolon E, Cadelina G, Gordon D, Pizzano J, Macaluso J, Soto L, Corradi J, Digianantonio K, Drulyte I, Morgan A, Quinn C, B\u00e9k\u00e9s M, Ferraro C, Chen X, Wang G, Dong H, Wang J, Langley DR, Houston J, Gedrich R, Taylor IC. Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4\/6 or PI3K\/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer Models. Clin Cancer Res. 2024;30(16):3549\u201363. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3465 . PMID: 38819400; PMCID: PMC11325148.","journal-title":"Clin Cancer Res"},{"key":"1900_CR38","doi-asserted-by":"publisher","unstructured":"Turner N, Huang-Bartlett C, Kalinsky K, Cristofanilli M, Bianchini G, Chia S, Iwata H, Janni W, Ma CX, Mayer EL, Park YH, Fox S, Liu X, McClain S, Bidard FC. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol. 2023;19(8):559\u2013573. https:\/\/doi.org\/10.2217\/fon-2022-1196. Epub 2023 Apr 18. Erratum in: Future Oncol. 2024;20(3):159\u2013161. doi: 10.2217\/fon-2022-1196c1. PMID: 37070653.","DOI":"10.2217\/fon-2022-1196"},{"issue":"3","key":"1900_CR39","doi-asserted-by":"publisher","first-page":"e055821","DOI":"10.1136\/bmjopen-2021-055821","volume":"12","author":"F Berger","year":"2022","unstructured":"Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bi\u00e8che I, Pradines A, De La Motte Rouge T, Canon JL, Andr\u00e9 F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC. PADA-1 investigators. Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1. BMJ Open. 2022;12(3):e055821. https:\/\/doi.org\/10.1136\/bmjopen-2021-055821 . PMID: 35241469; PMCID: PMC8896060.","journal-title":"BMJ Open"},{"issue":"9","key":"1900_CR40","doi-asserted-by":"publisher","first-page":"oyaf238","DOI":"10.1093\/oncolo\/oyaf238","volume":"30","author":"RB Barreto","year":"2025","unstructured":"Barreto RB. Assessing the clinical readiness of the SERENA-6 strategy. Oncologist. 2025;30(9):oyaf238. https:\/\/doi.org\/10.1093\/oncolo\/oyaf238 . PMID: 40711859; PMCID: PMC12422312.","journal-title":"Oncologist"},{"key":"1900_CR41","doi-asserted-by":"crossref","unstructured":"Merker JD, Oxnard GR, Compton C, Diehn M, Hurley P, Lazar AJ, Lindeman N, Lockwood CM, Rai AJ, Schilsky RL, Tsimberidou AM, Vasalos P, Billman BL, Oliver TK, Bruinooge SS, Hayes DF, Turner NC. Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review. J Clin Oncol. 2018;36(16):1631\u20131641. doi: 10.1200\/JCO.2017.76.8671. Epub 2018 Mar 5. PMID: 29504847.","DOI":"10.1200\/JCO.2017.76.8671"},{"issue":"224","key":"1900_CR42","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, Lee CC, Fecher LA, Gallia GL, Gibbs P, Le D, Giuntoli RL, Goggins M, Hogarty MD, Holdhoff M, Hong SM, Jiao Y, Juhl HH, Kim JJ, Siravegna G, Laheru DA, Lauricella C, Lim M, Lipson EJ, Marie SK, Netto GJ, Oliner KS, Olivi A, Olsson L, Riggins GJ, Sartore-Bianchi A, Schmidt K, Shih lM, Oba-Shinjo SM, Siena S, Theodorescu D, Tie J, Harkins TT, Veronese S, Wang TL, Weingart JD, Wolfgang CL, Wood LD, Xing D, Hruban RH, Wu J, Allen PJ, Schmidt CM, Choti MA, Velculescu VE, Kinzler KW, Vogelstein B, Papadopoulos N, Diaz LA Jr. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. https:\/\/doi.org\/10.1126\/scitranslmed.3007094 . PMID: 24553385; PMCID: PMC4017867.","journal-title":"Sci Transl Med"},{"issue":"11","key":"1900_CR43","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1016\/j.annonc.2024.06.018","volume":"35","author":"J van de Haar","year":"2024","unstructured":"van de Haar J, Roepman P, Andre F, Balma\u00f1a J, Castro E, Chakravarty D, Curigliano G, Czarnecka AM, Dienstmann R, Horak P, Italiano A, Marchi\u00f2 C, Monkhorst K, Pritchard CC, Reardon B, Russnes HEG, Sirohi B, Sosinsky A, Spanic T, Turnbull C, Van Allen E, Westphalen CB, Tamborero D, Mateo J. ESMO Recommendations on clinical reporting of genomic test results for solid cancers. Ann Oncol. 2024;35(11):954\u201367. https:\/\/doi.org\/10.1016\/j.annonc.2024.06.018 . Epub 2024 Jul 9. PMID: 39112111.","journal-title":"Ann Oncol"},{"issue":"2","key":"1900_CR44","doi-asserted-by":"publisher","first-page":"100399","DOI":"10.1016\/j.esmoop.2022.100399","volume":"7","author":"E Heitzer","year":"2022","unstructured":"Heitzer E, van den Broek D, Denis MG, Hofman P, Hubank M, Mouliere F, Paz-Ares L, Schuuring E, S\u00fcltmann H, Vainer G, Verstraaten E, de Visser L, Cortinovis D. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer. ESMO Open. 2022;7(2):100399. Epub 2022 Feb 21. PMID: 35202954; PMCID: PMC8867049.","journal-title":"ESMO Open"},{"issue":"22","key":"1900_CR45","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Gomez Moreno HL, Hu X, Jhaveri K, Krivorotko P, Loibl S, Morales Murillo S, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS. CAPItello-291 Study Group. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2023;388(22):2058\u201370. https:\/\/doi.org\/10.1056\/NEJMoa2214131 . PMID: 37256976; PMCID: PMC11335038.","journal-title":"N Engl J Med"},{"key":"1900_CR46","doi-asserted-by":"publisher","unstructured":"Andr\u00e9 F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, Iwata H, Conte P, Mayer IA, Kaufman B, Yamashita T, Lu YS, Inoue K, Takahashi M, P\u00e1pai Z, Longin AS, Mills D, Wilke C, Hirawat S, Juric D. SOLAR-1 Study Group. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019;380(20):1929\u20131940. https:\/\/doi.org\/10.1056\/NEJMoa1813904. PMID: 31091374.","DOI":"10.1056\/NEJMoa1813904"},{"key":"1900_CR47","doi-asserted-by":"publisher","first-page":"104485","DOI":"10.1016\/j.breast.2025.104485","volume":"82","author":"HS Rugo","year":"2025","unstructured":"Rugo HS, Bardia A, Gradishar WJ, Hamilton EP, Hurvitz SA, Jhaveri K, Mahtani R, Tolaney SM. Expert consensus on treating HR+\/HER2- metastatic breast cancer based on real-world practice patterns observed in the RETRACT survey of US oncologists. Breast. 2025;82:104485. https:\/\/doi.org\/10.1016\/j.breast.2025.104485 . Epub 2025 May 3. PMID: 40344957; PMCID: PMC12138406.","journal-title":"Breast"},{"issue":"19","key":"1900_CR48","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","volume":"377","author":"H Pan","year":"2017","unstructured":"Pan HH, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, Hayes DF. EBCTCG. 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med. 2017;377(19):1836\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1701830 . PMID: 29117498; PMCID: PMC5734609.","journal-title":"N Engl J Med"},{"issue":"27","key":"1900_CR49","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.2009.25.9655","volume":"28","author":"DL Hershman","year":"2010","unstructured":"Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, Fehrenbacher L, Gomez SL, Miles S, Neugut AI. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120\u20138. Epub 2010 Jun 28. PMID: 20585090; PMCID: PMC2953970.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1900_CR50","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529\u201337. https:\/\/doi.org\/10.1007\/s10549-010-1132-4 . Epub 2010 Aug 28. PMID: 20803066; PMCID: PMC3462663.","journal-title":"Breast Cancer Res Treat"},{"issue":"34","key":"1900_CR51","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, Toi M, Martin M, Shao ZM, Zhang QY, Martinez Rodriguez JL, Campone M, Hamilton E, Sohn J, Guarneri V, Okada M, Boyle F, Neven P, Cort\u00e9s J, Huober J, Wardley A, Tolaney SM, Cicin I, Smith IC, Frenzel M, Headley D, Wei R, San Antonio B, Hulstijn M, Cox J, O\u2019Shaughnessy J, Rastogi P. monarchE Committee Members and Investigators. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398. https:\/\/doi.org\/10.1200\/JCO.20.02514 . Epub 2020 Sep 20. PMID: 32954927; PMCID: PMC7768339.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1900_CR52","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.annonc.2024.10.015","volume":"36","author":"GN Hortobagyi","year":"2025","unstructured":"Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D. A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive\/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2025;36(2):149\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.015 . Epub 2024 Oct 21. PMID: 39442617.","journal-title":"Ann Oncol"},{"issue":"7","key":"1900_CR53","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1080\/14796694.2025.2459548","volume":"21","author":"EP Hamilton","year":"2025","unstructured":"Hamilton EP, Loibl S, Bachelot T, Gnant M, Niikura N, Park YH, Tolaney SM, Pistilli B, Rastogi P, Saini KS, Gioni I, Johnston S, Nunes R, Quintana A, Stuart M, Syta E, Walding A, Klinowska T, Mayer IA. CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+\/HER2- early breast cancer. Future Oncol. 2025;21(7):795\u2013806. Epub 2025 Feb 27. PMID: 40017004; PMCID: PMC11916374.","journal-title":"Future Oncol"},{"issue":"6","key":"1900_CR54","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone M, De Laurentiis M, Jhaveri K, Hu X, Ladoire S, Patsouris A, Zamagni C, Cui J, Cazzaniga M, Cil T, Jerzak KJ, Fuentes C, Yoshinami T, Rodriguez-Lescure A, Sezer A, Fontana A, Guarneri V, Molckovsky A, Mouret-Reynier MA, Demirci U, Zhang Y, Valota O, Lu DR, Martignoni M, Parameswaran J, Zhi X, Hamilton EP. VERITAC-2 Study Group. Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer. N Engl J Med. 2025;393(6):556\u201368. https:\/\/doi.org\/10.1056\/NEJMoa2505725 . Epub 2025. PMID: 40454645.","journal-title":"N Engl J Med"},{"issue":"21","key":"1900_CR55","doi-asserted-by":"publisher","first-page":"10366","DOI":"10.3390\/ijms262110366","volume":"26","author":"DP Narvaez","year":"2025","unstructured":"Narvaez DP, Cescon DW. Navigating Treatment Sequencing in Advanced HR+\/HER2- Breast Cancer After CDK4\/6 Inhibitors: Biomarker-Driven Strategies and Emerging Therapies. Int J Mol Sci. 2025;26(21):10366. https:\/\/doi.org\/10.3390\/ijms262110366 . PMID: 41226406; PMCID: PMC12609478.","journal-title":"Int J Mol Sci"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01900-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01900-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:58:50Z","timestamp":1787839130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01900-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1900"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01900-0","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest relevant to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is a narrative review and did not involve human participants or animal experiments; institutional review board approval and informed consent were not applicable.","order":2,"name":"Ethics","label":"Ethics statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative AI tools were used for language refinement only. The authors reviewed and take full responsibility for the final content.","order":3,"name":"Ethics","label":"Generative AI statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}